Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) FCF Margin (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed FCF Margin for 12 consecutive years, with 22.63% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 782.0% year-over-year to 22.63%, compared with a TTM value of 18.02% through Dec 2025, down 166.0%, and an annual FY2025 reading of 18.02%, down 122.0% over the prior year.
  • FCF Margin was 22.63% for Q4 2025 at Heron Therapeutics, down from 3.48% in the prior quarter.
  • Across five years, FCF Margin topped out at 8.96% in Q3 2024 and bottomed at 282.08% in Q2 2021.
  • Average FCF Margin over 5 years is 92.2%, with a median of 58.28% recorded in 2023.
  • The sharpest move saw FCF Margin crashed -7220bps in 2021, then skyrocketed 17822bps in 2022.
  • Year by year, FCF Margin stood at 221.0% in 2021, then soared by 43bps to 126.38% in 2022, then soared by 105bps to 6.44% in 2023, then plummeted by -573bps to 30.45% in 2024, then grew by 26bps to 22.63% in 2025.
  • Business Quant data shows FCF Margin for HRTX at 22.63% in Q4 2025, 3.48% in Q3 2025, and 29.77% in Q2 2025.